ReWind Therapeutics, a KU Leuven spin-off, receives a 15 million euro capital injection from pharmaceutical giants Boehringer Ingelheim and Merck as well as the Flemish Participation Society (PMV) and the Gemma Frisius fund. The funds will serve to further develop a medicine that focuses on recovery, rather than the symptoms.
Multiple sclerosis (MS) is a chronical disease which infects the nervous system by damaging myelin, a fatty substance which protects our nerves and conducts signals between the brain and nervous cells. Myelin damage prevents neural signals from passing through our nerves, resulting in severe neural problems eventually leading to chronic diseases such as MS. One in a thousand people in the Benelux are affected by MS, among them many adolescents.
Existing therapies for myelin disorders focus on relieving symptoms but aren’t capable of halting or curing the disease. ReWind Therapeutics aims to develop new forms of therapy that focuses on myelin damage, which is the cause of myelin disorders, resulting in a breakthrough for thousands of patients worldwide.
The company will use the funds to bring their first product to the clinic and to further expand their pipeline of novel drug candidates targeting myelin disorders.